NFL Biosciences Files Patent Application for Alcohol Reduction Drug NFL-301

NFL Biosciences has announced that it has filed a patent application in the United States for its drug candidate NFL-301, which focuses on reducing alcohol consumption. This patent application is a prerequisite for filing a pre-IND application with the FDA in the United States1 and a commitment to extend this new patent application internationally. Filing of a patent application in the United States for the formulation of NFL-301 and commitment to extend it internationally.

NFL Biosciences is pursuing its intellectual property strategy with the filing of a first patent for NFL-301. It aims to protect sustained-release formulations of extracts of kudzu, a plant used in traditional Chinese medicine, as well as their uses for the treatment of reduced alcohol consumption. As part of the co-development agreement set up in early 2022, NFL Biosciences and its industrial partner ATHENA Pharmaceuticals have developed a sustained-release form of kudzu extracts in the form of microgranules, NFL-301.

NFL Biosciences aims to develop the first oral-release drug based on kudzu extracts to combat excessive alcohol consumption. NFL-301 will be distinguished from kudzu-based nutritional supplements by: its positioning as a drug that complies with regulations relating to marketing authorizations (AMM); its higher dosage and in line with the range of efficacy expected in countries that limit daily concentrations as a nutritional supplement (eg France, Belgium and other European countries).France, Belgium and other European countries) ; its quality, controlled according to good manufacturing practices (GMP); its prolonged effect allowing a single daily dose; its flexibility for taking and adapting dosage levels thanks to the microgranule form, compared to capsules or tablets. Preparation of a pre-IND application in the United States for NFL-301: NFL is preparing a pre-IND application in the United States, which is expected to be submitted in September, in order to obtain FDA approval for the process of manufacturing, product quality and development strategy up to marketing authorization.

2023-07-18 06:00:00
#NFL #Biosciences #Announces #Filing #U.S #Patent #Application #Alcohol #Reduction #NFL301 #Preparation #Preliminary #FDA #Submission